Drug Eluting Stents: Past, Future & Dual Anti-Platelet Therapy When is Stopping Safe
|
|
- Sybil Chapman
- 8 years ago
- Views:
Transcription
1 Disclosure Statement of Financial Interest Drug Eluting Stents: Past, Future & Dual Anti-Platelet Therapy When is Stopping Safe Louis A. Cannon, MD, FACC, FSCAI, FACP Program Director, Heart & Vascular Institute of Northern Michigan Hospital Founder, President, The Cardiac & Vascular Research Center of Northern Michigan Lub Dub 214 Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Grant/Research Support Abbott Vascular Fogarty Foundation McLaren Northern Michigan Consulting Fees/Honoraria Boston Scientific Abbott Vascular Medtronic Covidien Major Stock Shareholder/Equity BioStar Ventures CVRCNM Ownership/Founder BioStar Ventures CVRCNM Ownership KONA CVI Ablative Solutions Guided Delivery Systems MiCardia Cardiac MD / Phoenix Royalty Income, Intellectual Property Rights, Other Financial Benefit None The Problem of Dual Antiplatelet Therapy (DAPT) and Anticoagulation Patient: Mr John Average CHADS2VASC -- <8< 8mm focal RCA 2.5 mm in diameter with distal haze likely fractured plaque LL.? Multiple Issues & Multiple studies at Different Times with Different Stents, s and Drugs with Differing Populations BMS DES?? BMS? Which DES? Which Anti-Plt Agent How Long? Study Support and the Challenge of Medical Legend DES: ION 2.5 mm / 14 mm post to 26 atm with NCB Smaller diameter and diabetes = DES benefit GOAL: Correct diameter sizing complete apposition and circular strut expansion Normal artery to normal artery 1
2 The Problem of Dual Antiplatelet Therapy (DAPT) and Anticoagulation S.P., 86 y/o male, arterial hypertension / diabetes mellitus Stenting January 21 st 213 Did not agree to ablation for atrial flutter Telephone follow-up May 13 th 213: free of symptoms RECOMMENDATION:4 weeks triple therapy with ASA 81 mg/d + Clopidogrel 75 mg/d and Rivaroxaban 15 mg/d for 4 weeks Then Clopidogrel discontinued Traditional Predictors of Restenosis Predicted in-stent restenosis rates 1 Diabetes, Long Lesions & Small Vessels, contribute to Restenosis Lesion Length MLD 1 mm 15 mm 2 mm 25 mm Diabetics 2.5 mm 35% 39% 43% 46% 3. mm 23% 26% 3% 33% 3.5 mm 15% 17% 19% 22% 4. mm 9% 1% 12% 14% Non-Diabetics 2.5 mm 27% 3% 33% 37% 3. mm 17% 19% 22% 25% 3.5 mm 1% 12% 14% 16% 4. mm 6% 7% 8% 1% 1 Ho, AHA, Looking From The Inside Out? Metal to Surface Area vs. Restenosis Diameter 2.5 mm Metal to Surface Area 22.4 % 3. mm 19. % 3.5 mm 16.4 % TCT: Moussa, Columbia Univ Med Ctr, CRF Late Loss by Vessel Size & % Diameter Stenosis --Small Vessels Lose Big RVD 4. mm 3.5 mm 3. mm mm 4.mm 2.5 mm 2. mm.45mm.45mm.45mm.45mm.45mm Late Loss.9 mm.9 mm.9 mm.9 mm.9 mm Diameter Stenosis 23% 26% 3% 36% 45% TCT: Moussa, Columbia Univ Med Ctr, CRF What s the literature on small vessels Doctor 1998: Small Vessels (SV) were < 3. mm 1,2 TLR rates are SV 3.mm SV binary restenosis rates 3 Pts with SV often have complexity: a) DM b) Long c) Tapered d) calcium 21: Small Vessels are 2.5 mm 1 Columbo, et al., J of Invasive Cardiol., Vol. 13, No. 6, June 21.2 Scheile et al, Catheterization and Cardiovascular Diagnosis 44: 77-82, Fitzgerald, P. et al., Contribution of Localized Calcium Deposits to Dissection after Angioplasty, Circulation 1992, Vol. 86, No Mintz, American Journal of Cardiology, ACC/AHA Guidlines 2
3 Balance of Efficacy and Healing Premature Discontinuation of Anti-Platelet Therapy FPO Premature Discontinuation of Anti-Platelet Therapy is the most important predictor of stent thrombosis after implantation * Stent struts not covered by neointima Too Little?? Optimal? Too Much?? Higher rates of TLR Results: At 9 month follow-up, 29 pts had stent thrombosis (1.3%) Among the 29 patients, 13 died (case fatality rate 45%) Negative Late Loss Common reasons for discontinuation include: Noncompliance Follow on procedures: surgery, dental, biopsies Resistance to clopidogrel, aspirin.1.4 In-stent Late Loss (mm).6 *Lakovou et al. Incidence, predictors, and outcomes of thrombosis after successful implantation of drug-eluting stents. JAMA. May Late Stent Thrombosis Factors to Consider Of the 15 DES thrombosis cases, 6 (4%) were LST. This could be related to delayed stent endothelialisation, late stent malapposition...and even a localized sensitivity to the polymer. * Late Stent thrombosis: After Anti-platelet Discontinuation CYPHER TAXUS Delayed Endothelialization Late Stent Thrombosis Late Incomplete Apposition Usually associated with minor surgical procedures! Hypersensitivity/ Inflammation Day *Moreno et al. Drug-eluting stent thrombosis, results from a pooled analysis including 1 randomized studies. Madrid, Spain; (JACC 25) McFadden EP et al. Lancet 24; 364: Applying Guidelines on John Average All randomized Controlled medical studies published in the literature do NOT apply to Mr John Average Age Exclusion 5 year follow up NSTEMI Exclusion with troponin bump risk of thrombus and follow MACE Pt on Rivaroxaban tooo high a bleeding risk contributing to MACE (interactions unknown) Depressed EF < 35% (longevity and MACE secondary to other causes Real World studies?? Are Not Randomized, Controlled, Blinded studies Are Ethnically disparate, Genetically diverse, When published,. they are already historical studies What is the Minimum Duration of DAPT Duration after PCI with DES in Patients with Stable CAD? 25: 6-12 months 21: 6-12 months 27: 12 months 211: at least 12 months Why the Difference?? The Stent, s, Drug is different we are Europeans Hx 3
4 Fully published randomized studies for DAPT duration after the guidelines have been finalized: Every month of DAPT prolongation counts for increased bleeds REAL/ZEST LATE (21) EXCELLENT (212) PRODIGY (213) DAPT Duration 1 year vs. 2 years 6 months vs. 1 y 6 months vs. 2 y Message no advantage of 2 years (probably worse) no signif. difference no advantage of longer DAPT,91,92,93,94,95 24 mo DAPT (PP) 1 mo DAPT (BMS) 6 mo DAPT (PP) DAPT Bleeding risk: 3.8%/y ASA bleeding risk: %/y Bleeding hazard.2%/month Guidelines are Guidelines based on Medical Legends and can be used for the average patient in the average practice by the average physician in the average situation, yesterday In an average patient on average,96 ASA mono-tx,97,98 ASA mono-tx,99 1, Survival Time (Days) SO, lets call all the patients in our practices and D/C DAPT if longer than 6 months Prodigy and others were in 3 rd 4 th generation stents Exclusion criteria for most studies: Anti coagulants, age, poor EF Multiple stents Lesion length and diameter Intra Coronary Thrombus Need for Overlapping stents Major side Branches Saphenous vein bypass graft to epicardial vessel Any patient with a diseased saphenous vein graft Hold the phone call ION Stent Strut Thickness compared to other DES ION, TAXUS Express, TAXUS Liberte Stents are trademarks of Boston Scientific Corporation; XIENCE V is a trademark of Abbott Laboratories group of companies; Cypher is a trademark of Cordis Corp.; Endeavor is a trademark of Medtronic Inc. Everolimus-Eluting Stents Everolimus concentration: 1 ug/cm 2 : PBMA & PVDF-HFP (7mm thickness) XIENCE V / PROMUS (CoCr-EES) PROMUS Element (PtCr-EES) 18% Chromium 33% Platinum 3% Iron 1% Nickel 15% Tungsten 52% Cobalt 2.6% Molybdenum 9% Nickel.5% Manganese 37% Iron 2% Chromium 1.5% Manganes e PtCr Stent Platform Clinical Program: Paclitaxel and Everolimus ION * Paclitaxel PERSEUS Study Program 1-year Results ACC 21 2-year Results TCT 211 PROMUS Element Plus Everolimus PLATINUM Study Program 9 month QCA TCT 21 1-year RCT Results ACC 211 PBMA=poly (n-butyl methacrylate) (primer layer); PVDF-HFP=poly (vinylidene fluoride-co-hexafluoropropylene) (drug matrix layer) 23 *The ION Stent is commercialized as the TAXUS Element Stent outside the U.S. The PERSEUS and PLATINUM studies are sponsored by Boston Scientific Corporation. The PROMUS Element Plus Stent is an investigational device. Limited by United States Federal Law to investigational use in the U.S. Not for sale in the U.S. 4
5 Event Rates (per Patient, %) Micron (µ) BSC JNJ ABT MDT 7/8/214 PERSEUS WH (Overall Study) 12-Month Clinical Outcomes in All Patients TAXUS Express Stent (N=32) TLF: ischemia-driven TLR, or MI/cardiac death related to the target vessel. MACE: MI, TVR, cardiac death TLF MACE TLR All-Cause Death ION * Stent (N=942) P=.78 P=.86 P=.6 P>.99 P=.34 P=.17 P>.99 Overall MI.7.5. (19/313) (52/922) (24/313) (68/922) (14/313) (35/922) (2/314) (6/922) (/313) (5/922) Q-MI 2.9 P=.48 T. Express 2.9% ION 2.2% 1.6 (9/313) (15/922) NQWMI.3.4 (1/313) (4/918) ST (ARC Def/Prob) 12m DAPT compliance 89%, both groups U.S. Drug-Eluting Stent Launches 211 through 217+ Projections* ION PtCr Stent PROMUS 2.25mm Xience V Nano PROMUS Element Plus PtCr NEVO launch date may change. Oct 19, 21, J&J announced suspension of enrollment for OUS NEVO II clinical trial citing balloon catheter performance issues. Enrollment began in Aug 21, Xience Prime Endeavor Resolute TM OMEGA TM PtCr BMS Nevo * Resolute TM Integrity TM SYNERGY Program***? ThinMan TM * Metallic Bioabsorbable Stent Program*** Bioabsorbable Stent Program*** BVS * Presented by Louis Cannon, MD at TCT 21. *The ION Stent is commercialized as the TAXUS Element Stent outside the U.S. The PERSEUS WH and PERSEUS SV studies are sponsored and funded by Boston Scientific Corporation. Introduction: Bioabsorbable polymer Durable polymer coatings on drug-eluting stents have been associated with chronic inflammation and impaired healing. SYNERGY Stent Abluminal Bioabsorbable and Drug Bioabsorbable polymer (PLGA) Applied only to the abluminal surface (rollcoat) Thin strut PtCr Stent Potential advantages of bioabsorbable polymer stents: Reduced polymer load Short-term polymer exposure may Decrease risk of late events including ST and TLR Reduce required duration of DAPT and risk if interrupted Durable Permanent + Drug 36 Around Stent Current Durable Abluminal Bioabsorbable PLGA Bioabsorbable + Everolimus * on Abluminal Side of Stent * 2 doses of everolimus evaluated: one similar to PROMUS Stent and one that is half the dose Presented by Ian Meredith, MBBS, PhD at TCT 21 Study sponsored by Boston Scientific Corporation. Not for sale. Abluminal Bioabsorbable Relative Thickness Percutaneous Coronary Intervention Multivariate correlates of cumulative late mortality (7,16 patients discharged alive post PCI, followed 1.4+/- ½ years) Hazard Ratio ± 95% CI (p<.5) ~5µ 6-8µ ~15µ 14µ 5-12µ Renal Impairment Diabetes mellitus CK elevation (8xULN)* Saphenous vein graft Prior MI Unstable angina Left main PCI Elevated cholesterol Current smoker Advanced age Bioabsorbable Abluminal (Thickness) Red Cell (Diameter) TAXUS Liberté (Thickness) Neutrophil (Diameter) Human Hair (Thickness) *In the absence of new Q waves CAUTION: Under Development. Not for sale. Stone et al Circ 21;14:
6 Patients (%) Target Lesion Failure (%) Event Rates (per Patient, %) 7/8/214 SPIRIT IV: Impact of Diabetes (TLF 1-yr) Sites of action of rapamycin and paclitaxel PROMUS (Xience V ) Stent TAXUS Express Stent Type II Diabetes P<.1 P=.8 Hyperglycemia Free Fatty Acids Insulin Receptor Hyperinsulinemia ROS PKC IKKb IRS-1 Shc PI 3 kinase PDK-1 Akt mtor Sos Ras Olimi Akt p 7S6K Cell Cycle Effectors Raf 52/ /815 49/761 26/379 enos S6 MAPKK TLF=Cardiac Death, Target Vessel MI, or ischemia driven TLR 1 year = 365 ± 28 days NO Protein synthesis Vasodilation Inhibits SMC Migration Anti-thrombotic MAPK (ERK1,2, p38, JNK) Vasoconstriction Mitogenesis Pro-inflammatory factors Paclitaxel Stone, G. N Engl J Med 21;362: The PROMUS Stent is a private-labeled XIENCE V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation. XIENCE V is a trademark of Abbott Laboratories group of companies. Caution: The safety and effectiveness of the TAXUS Stent Systems, ION Stent and PROMUS Stent have not been established in patients with diabetes mellitus. Caution: The safety and effectiveness of the TAXUS Stent Systems and ION Stent have not been established in patients with diabetes mellitus. In high glucose: Inhibition of SMC migration by Paclitaxel is preserved; Sirolimus loses effects The IC5 for sirolimus on migration is <.1 ng/ml, but > 1 ng/ml under high glucose conditions. The effect of sirolimus to inhibit smooth muscle migration is thus reduced by at least 1-fold. PERSEUS Diabetes Substudy Unadjusted 12-Month Outcomes ION *Stent-Treated Patients 2 Non-Diabetic (N=852) Diabetic (N=314) Patterson C, Arteriosclerosis, Thrombosis, and Vascular Biology, 26;26; P=.17 P=.11 P=.29 P=.6 P=.95 P= TLF ** MACE TLR All-Cause Death **TLF: ischemia-driven TLR, or MI/cardiac death related to the target vessel. MACE: MI, TVR, cardiac death Baseline Lesion Differences Non-Diabetic (N=852) (45/836) (23/34) (63/836) (32/34) (32/836) (16/34) (4/837) (5/33) (16/836) (6/34) MI Diabetic (N=314).4 P Value RVD (mm) 2.67± ±.55.2 Length (mm) 13.53± ± (3/834) (2/299) ST (ARC Def/Prob) Presented by Louis Cannon, MD at TCT 21. *The ION Stent is commercialized as the TAXUS Element Stent outside the U.S. The PERSEUS study is sponsored by Boston Scientific Corporation. Caution: The safety and effectiveness of the ION Stent have not been established in patients with diabetes mellitus. Stent Thrombosis - ARC Def/Prob 3-Year Follow-up No. at risk CoCr-EES (N=749) PtCr-EES (N=758) HR [95% CI] = 1.23 [.33, 4.57] P =.76 CoCr-EES PtCr-EES PtCr- EES CoCr- EES Months Since Index Procedure ARC Definite Stent Thrombosis* Early (<3d) Late (3d -1yr) Very Late (1-3 yrs) P>.99 n=1 n=2 n=2 n=3 n=1.7% (N=5/77).6% (N=4/675).7%.5% Antiplatelet Medication Usage Medication CoCr-EES PtCr-EES P (N=749) Discharge (N=758) value Aspirin 99.6% 98.9%.14 Thienopyridine 99.2% 98.9%.61 Aspirin + Thienopyridine 98.9% 98.%.15 1 Year Aspirin 93.7% 94.7%.41 Thienopyridine 82.7% 84.8%.29 Aspirin + Thienopyridine 8.5% 83.4%.13 2 Years Aspirin 92.7% 94.8%.9 Thienopyridine 5.8% 53.7%.25 Aspirin + Thienopyridine 48.% 51.4%.19 *There were no adjudicated ARC probable ST events through 3 years of follow-up; binary rates Aspirin + Thienopyridine 42.9% 42.7%.93 CoCr-EES: 1 ST occurred during 1-2 years; PtCR-EES: 1 ST occurred during 1-2 years and 1 during 2-3 years ARC=Academic Research Consortium; Def/Prob=definite/probable; ST=stent thrombosis Years Aspirin 95.2% 95.3%.94 Thienopyridine 46.5% 46.%.84 6
7 Delayed Endothelialization Overlap more than Doubles the Toil and Troubles Crush Technique SES PES Try to re-cross two layers of struts into the SB, and finish up with kissing balloons BMS Overlap BMS Overlap Results will vary, depending on the angulation of the SB Conclusions: BMS showed far greater endothelialization than DES Lack of coverage highlighted in areas of overlap Less surface coverage by endothelial cells in PES 37 than SES Finn AV. Circulation. 25;112: Ormiston 23 Crush Technique Position both stents simultaneously. Deploy the SB first, then crush it with the main branch stent Inflammation Overlapping SES vs PES Conclusions: DES further delays arterial healing and promote inflammation Compared to SES, PES induce greater: Fibrin deposition Medial cell loss WBC Infiltration Late Neointimal Hyperplasia Ormiston 23 Finn AV. Circulation. 25;112: Mr John Average Deserves : Guideline Based Medical Care Patient: Mr John Average Not so average Guidelines do not apply (including CHADS2VASC hx) In Conclusion: Stents have been in Rapid Evolution: - Smaller diameter, enhanced flexibility, trackability, Visibility - Less recoil, Less non-biodegradable (inflammatory) polymer Studies are very controlled protocol based populations Patients exist in uncontrolled populations Medicine is not pre-programmed robotics Many Guidelines are Medical Legends Studies of yesterday do not reflect practice of today, especially in the USA, when worldwide studies do not reflect current average drugs, our genetics, our diet, exercise pattern or our practices, or the US average patient, on average THANK YOU 7
8 3.5% upper boundary non-inferiority margin 7/8/214 PERSEUS WH, ATLAS and SPIRIT Trials Data Sets in Absence of Small Vessels TAXUS ATLAS WH 15% 1% 5% 12.3% 12.5% RVD 2.5mm p=.94 6% 4% 2% SPIRIT III 4.4% 5.1% RVD > 2.775mm subset RR = 1.17 [.46, 2.97] Primary Endpoint Target Lesion Failure at 12 Months Population Difference [2-sided 95% CI] (1-sided UCB) CoCr- EES (N=762) PtCr- EES (N=768) P Difference Value [2-sided 95% CI] (noninferiority) (superiority) % 6% 4% 2% % (n=978) 4.7% (n=867) 12 month MACE* (n=45) SPIRIT IV 3.9% (n=91) 12 month TLF* TAXUS Express Stent *Cardiac Death, MI, or ischemia-driven TVR RVD > 2.75 mm subset HR =.83 [.49, 1.41] *Cardiac Death, target-vessel MI, or ischemia-driven TLR TAXUS Liberté Stent % 8% 5% 3% % (n=137) 12 month MACE* PERSEUS WH 6.1% (n=313) (n=274) 5.6% (n=922) 12 month TLF* Xience V (PROMUS ) Stent *Cardiac Death, MI, or ischemia-driven TLR RVD 2.75mm P=.78 *Target Vessel Cardiac Death, targetvessel MI, or ischemia-driven TLR ION Stent ATLAS WH: BSC Data on File; SPIRIT III: Gregg Stone, et. Al. JAMA: 28 April (299)16: SPIRIT IV: Presented by Gregg W. Stone, MD, TCT 29 ( + total patient N= 1351 reported only). The PROMUS Stent is a private-labeled XIENCE V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation. XIENCE V is a trademark of Abbott Laboratories group of companies. SPIRIT is sponsored by Abbott. *The ION Stent is commercialized as the TAXUS Element Stent outside the U.S. The PERSEUS WH and PERSEUS SV studies are sponsored and funded by Boston Scientific Corporation. Per protocol (1º endpt) Intentto-treat PtCr-EES better 2.13% 1-sided UCB 2.1% 1-sided UCB CoCr-EES better 2.9% 3.4%.5%.1 (21/714) (25/731) [-1.3%, 2.3%].6 3.2% 3.5%.3%.9 (23/727) (26/742) [-1.5%, 2.2%].72 UCB=upper confidence bou1n1d 8
9 TAXUS V Trial IVUS Enriching the Understanding Of Efficacy and Healing Control Stent 31.8 % Net Volume Obstruction TAXUS Express 2TM Stent 13.1 % Net Volume Obstruction 59% reduction 9
10 Balance of Efficacy and Healing Incomplete Apposition DES studies with available IVUS follow-up FPO Stent struts not covered by neointima Too Little?? Optimal? Too Much?? Higher rates of TLR % I A Incomplete Apposition Negative Late Loss.1.4 In-stent Late Loss (mm) T AXUS I I T AXUS I V T AXUS V RAVEL1 SI RI US1E- SI RI US2 DI ABET ES3 n=15/119 n=4/99 n=17/148 n=1/41 n=18/14 n=nr n=nr P=ns P=ns P=ns P=nr P=nr P=.7 P=.1 1. Cypher Stent DFU 2. E-SIRIUS IVUS presentation, AHA 23 3.Pilar, Jimaenez-Quevedo, et. al. The DIABETES Trial. 9 month IVUS,, ACC 25 TAXUS TAXUS Control Cypher TM Cypher TM Control For reference purposes only. Late-Incomplete Apposition Potential for Stent Thrombosis Baseline Follow-up In a Taxus and Cypher study of patients with late incomplete apposition upon clopidogrel discontinuation: Late-Incomplete Apposition Potential Mechanisms Baseline Follow-up No Remodeling No Remodeling 2% had stent thrombosis* Positive Remodeling Positive 59 6 * Study by Dr. Abizaid, presented at TCT 25. Remodeling Source: Dr. Peter Fitzgerald 1
11 Late Stent Thrombosis Factors to Consider Discontinuation of Anti-Platelet Therapy Delayed Endothelialization Late Stent Thrombosis Late Incomplete Apposition Thank you Hypersensitivity/ Inflammation 61 11
Antonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationThe Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationPooled RESOLUTE Clinical Program
The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationDrug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationAdvances in Stent Technology
Nurse/Technologist Symposium Advances in Stent Technology Antonietta Tolentino, CCRN, MSN, ANP-C Adult Nurse Practitioner, Cardiac Catheterization Laboratory The Zena and Michael A. Weiner Cardiovascular
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationCopenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationOstial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationPreoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia
Preoperative Cardiac Stents Perioperative Management Mark A. Taylor, MD Department of Anesthesia Revasc prior to NCS If it offered long term benefit-- --made sense to do it 1-22 vessel CAD by angiogram,
More informationOptimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
More informationIntracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationCoronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)
Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I
More informationThe Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
More informationPOST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS
POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS Post Stenting Dual Antiplatelet Therapy When can I stop it? Intracoronary stenting is a frequent intervention for
More informationClinical Programs. Medtronic Coronary Stent Systems. driver BMS
Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
More informationPresenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
More informationDual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes
Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes Robert W. Yeh, Dean J. Kereiakes, P. Gabriel Steg, Stephan Windecker, Michael J.
More informationIs Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
More informationOCT STEMI: OCT guidance during stent implantation
OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More informationDéjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB
Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB Didier Carrié CHU Toulouse APPAC 4 Juin 2014 Aucun conflit
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationBRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the
Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators
More informationThe Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,
More informationJUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
More informationDo método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole
More informationClinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
More informationCARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
More informationA Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
More informationOCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS
OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS Division of Cardiology, Mount Sinai Hospital, New York, NY, USA Yuliya Vengrenyuk, PhD; and Annapoorna Kini, MD OCT ASSESSMENT OF CUTTING
More informationStatus of Drug-Eluting Coronary Stents
Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided
More informationOPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent
Main Arena III - Plenary Sessions XVI Late Breaking Clinical Trials III - Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy
More informationGUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA
More informationEarly healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents
Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents One-month results of the study Ida Riise Balleby 1, Trine Krejberg Ørhøj 1, Christian Juhl
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationThe BASE-ACS Trial. A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome. 18 months Follow-up results
The BASE-ACS Trial A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome 18 months Follow-up results Pasi Karjalainen, MD, PhD, adjunct Professor on behalf of the
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationControversies in the use & implementation of drug-eluting stent technology
Review Article Indian J Med Res 136, December 2012, pp 926-941 Controversies in the use & implementation of drug-eluting stent technology Brandon K. Itagaki * & Somjot S. Brar *,** * Regional Cardiac Cath
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationPCI vs. CABG for Left Main Disease
The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease
More informationPerioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time
Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationDrug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate
Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention
More informationTAXUS Express 2. Paclitaxel-Eluting Coronary Stent System. Patient Information Guide
TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System Patient Information Guide 1 Table of Contents Coronary Artery Disease...2 Who Is at Risk?...3 Diagnosis of Coronary Artery Disease...3 Treatment
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationEverolimus Eluting Coronary Stent System. Patient Information Guide
Everolimus Eluting Coronary Stent System Patient Information Guide Table of Contents Coronary Artery Disease (CAD)...5 Your Heart...5 What is CAD?...5 What are the Symptoms of CAD?...5 What are the Risk
More informationYukon Choice DES + Translumina - The polymer-free DES solution. www.translumina.de. Coronary Stent System for Drug Application
Coronary Stent System for Drug Application Yukon Choice DES + new catheter polymer-free DES Translumina - The polymer-free DES solution www.translumina.de A First Class Stent The YUKON Choice DES+ is the
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationEditorial. Adult Cardiology - Meta-analysis
Editorial Adult Cardiology - Meta-analysis Simple Versus Complex Bifurcation Stenting Strategies A Meta Analysis of Randomized Controlled Trials in the Drug Eluting Stent Era Ana Beatriz R. Medrano, MD
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationAngioplasty and Stent Education Guide
Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease...2 What is coronary artery disease...3 Coronary artery disease treatment options...4 What are coronary artery
More informationUnderstanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients
Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options A Guide for Patients Coronary Artery Disease If you or a member of your family has been diagnosed with coronary artery
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationOrsiro Hybrid Drug Eluting Stent Industry's first hybrid DES
Vascular Intervention Drug Eluting Stents Orsiro Orsiro Hybrid Drug Eluting Stent Industry's first hybrid DES Orsiro An ideal combination of passive and active components The Orsiro Hybrid Drug Eluting
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationOverview of Newer Stent Devices for Aneurysm Treatment
Overview of Newer Stent Devices for Aneurysm Treatment Randall C. Edgell, M.D. Associate Professor Vascular and Interventional Neurology Saint Louis University Disclosure Outcome adjudication for THERAPY,
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationFFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationA Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease A Report of the
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationNew Approaches to, and Indications for, Antiplatelet Therapy
New Approaches to, and Indications for, Antiplatelet Therapy Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School Chief, Hematology Section, VA Boston Healthcare System Director, Thrombosis
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationPolymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial
Polymer-Based, Paclitaxel-Eluting Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O'Shaughnessy, Tift Mann, Thomas
More informationPlatelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More information06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
More informationContents. MicroPort Scientific Completes Acquisition of Wright Medical's OrthoRecon Business
January 2014 MicroPort Scientific Corporation (HK: 853) Volume 28 MicroPort Scientific Completes Acquisition of Wright Medical's OrthoRecon Business SHANGHAI January 10, 2014 MicroPort Scientific Corporation
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationRISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationESC PCI Guidelines: / Sigmund Silber et al. 1
For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationDrug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review)
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review) Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A This is a reprint of a Cochrane review, prepared
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More information